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Peripheral blood lymphocytes from some of patients 
with mycosis fungoides disease showed decreased ability 
to form rosettes with sheep erythrocytes_ This decreased 
'percentage of E-rosette forming cells could be normal-
ized when those cells were incubated in culture for 20 
hr. Since these data led us to considering a possible 
inhibitory factor present in patients' sera, we tested their 
ability to inhibit E-rosetting by T lymphocytes from 
normal donors, and found that sera from mycosis fun-
goides patients with low levels of E-rosetting blood lym-
phocytes showed greater inhibitory effect on E-rosette 
formation by normal T cells when compared to those 
either from normal donors or from mycosis patients who 
had almost normal levels of E-rosetting blood lympho-
cyte number. The E-rosette inhibitory factor was sensi-
tive to 2-mercaptoethanol treatment and was copurified 
with serum IgM by ammonium sulfate precipitation and 
by sequential gel filtrations, suggesting that it might be 
an anti-T lymphocyte antibody naturally occurring dur-
ing the disease process. 
It has been reported that mycosis fungoides (MF) is one of 
the T cell malignancies [1-3], which usually undergoes 3 differ-
ent stages, i.e., eczematous, plaque, and tumor stages. However, 
D'emblee type occurs at the tumor stage and has poorer rrog-
nos is [4]. . 
Recently, Nordqvist and Kinney [5] has reported that the 
MF patients have decreased percentage of peripheral blood 
lymphocytes (PBL) rosetting with sheep red cells (E). In the 
present study, we have tested E-rosette formation ofPBL from 
the MF patients and have found that a certain serum factor 
might be responsible for the lowered number of E-rosetting 
PBL in the MF patients. This factor might be a naturally 
occuring anti-T cell antibody because it was sensitive to 2-
mercaptoethanol treatment and was copurified with serum IgM 
by using ammonium sulfate precipitation and sequential gel 
filtrations. . 
MATERIALS AND METHODS 
Patient Selection and Staging 
Studies were performed in 5 MF patients vary ing in stages (Table I) , 
who were collected between 1978 and 1979. The. diagnosis was made by 
clinical criteria as well as by histological examinations. 
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Abbreviations: 
BSA: bovine serum a lbumin 
C: complement 
CI: cytotoxic index 
E: sheep red cells 
%EI: percentage of E-rosette inhibi t ion 
FCS: feta l calf serum 
2-ME: 2- mercaptoethanol 
MF: mycosis fungoides 
OY A: ovalbumin 
PBL: peripheral blood lymphocytes 
PBS: phosphate buffered saline 
Lymphocyte Separation 
Mononuclear cells were separated from peripheral blood by centrif-
ugation on a FicoLl-Conray gradient (d = 1.080) at 250 g for 20 min. 
Cells at the in terface were collected, washed 3 times with phosphate-
buffered saline (PBS) and suspended in RPMI-1640 medium. More 
than 98% of cells were viab le after washing, as determined by try pan 
blue dye exclusion test [6]. 
E-rosette Formation 
The abili ty of PBL to form spontaneous rosettes with neuraminidase-
treated sheep E was examined by the method of Bentwich et al [7]. 
Briefly, equal volumes (0.1 ml) of 0.5% E and PBL (5 X IOG/ mI) were 
admixed and incubated at 37°C for 5 min. The mixture was then spun 
at 200 g for 5 min and kept at 4°C for 1 hr. The cells were gently 
resuspended and the percentage of ce lls with more than 2 sheep E were 
coun ted. 
E-rosette Inhibition T est 
The ability of sera from MF patients to inhibi t E-rosette formation 
of PBL from normal donors was studied by the method previously 
described [8]. Briefly, 0.1 ml of normal PBL (5 X 10"/mI) was mixed 
with 0.1 ml of undiluted human sera or fractionated sera (20 mg 
protein/ ml) and incubated at 20°C for 30 min. T he cells were washed 
3 t imes with PBS, suspended in 0. 1 ml of RPMI-1640 and mixed with 
0.1 ml of 0.5% sheep E. The mixture was centri fuged and incubated at 
4°C for 1 hr. The numbers of E-rosetting cells were coun ted, estimating 
the percentage of E-rosette inhibition (%EI) as 
Untreated %RFC - Serum-treated %RFC 
Untreated %RFC X 100 (%) 
Ammonium Sulfate Precipitation 
Six volu mes of human serum were admixed wi th 4 vol of saturated 
ammonium sulfate solu tion (PH 7.0). Precipitates which contained 
gamma-globulin were collected by centrifugation at 10,000 g for 15 min. 
The supel'l1atant was collected and dia lyzed against PBS. The pellet 
was dissolved in an appropriate amoun t of PBS and reprecipitated with 
40% NH"SO". The precipitates were dissolved in PBS and dialyzed 
against PBS for 24 111" in a cold room. 
Treatment of Human Gamma-globulin with 2-merca.ptoethanol (2· 
ME) 
Crude gamma-globulin (20 mg/ ml) prepared by ammonium sulfate 
precipi tation or undilu ted human serum was mixed with 2-ME to give 
a fmal concentration of 0.05 M, which was a nontoxic dose for human 
PBL. After incubation at 20°C for 1 hr, 2-ME-treated samples were 
utilized for E-rosette inhibition experiments. 
Gel Filtration 
A column (1.8 X 50 cm) was prepared with either Bio-Gel A1.5m or 
Bio-Gel A5m (Bio-Rad Laboratories, Hichmond, Ca.) and equilibrated 
with a running buffer of PBS (PH 7.4). Descending chromatography 
was performed at 4°C with a flow rate of 2 mI/hr. The column was 
cal ibrated for molecular weight estimation with purified human IgG, 
bovine serum albumin (BSA) and ovalbumin (OYA). 
Cytotoxicity Test 
Complement-dependent cytotoxicity was determined by trypan blue 
dye exclusion test using normal rabbit seru m as a sow'ce of complement 
[6]. Equal volumes of target T ce ll suspension (5 x lOG/mI), normal or 
MF patient's serum and complement (C) were mixed and incubated at 
37°C for 30 min. Lysed cells were judged by uptake of trypan blue, 
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TABLE I. Patient selection and stag ing 
Cytogram (%)' Skin teste 
Case" Age Sex Stage WBC nllmber %E-RFC" 
Lymph. Gran. Mono. PPO DNCB 
1 41 Male Tumor 14,200 18 81 1 + 25 
2 55 Female Tumor 6,800 15 84 1 11 
3 78 M ale Plaque 9,900 10 89 1 nde 16 
4 56 Female Plaque 3,500 25 73 3 + + 70 
5 64 Male P laque 7,000 28 70 2 + + 51 
" Case 1 was a 41-yr-old male in the tumor s tage, who had been considered to be a very rare case of D'emblee type. Case 2 was a 55-yr-old 
female also in the tumor stage. Case 3 was a 78-yr-old male in the plaque stage at fU'st, followed by relatively rapid clinical course to reach finally 
the tumor stage. Case 4 and 5 were in the tumor stage. Case 1 to 3 had a decreased percentage of E-rosetting PBL. (%E-RFC) when tested before 
chemotherapy, whereas Case 4 and 5 showed almost normal %E-RFC in the blood. T he former patients have aU died in spite of chemo and 
radiotherapy but the latter pa tients are a ll alive with appropriate treatment. 
" Whi te blood cells (WBC) were differentia ted morphologically into either lymphocytes (Lymph.) granulocytes (Gran.) or monocytes (Mono.). 
,. Cutaneous delayed type hypersensit ivity reactions measm ed 48 hr after treating pat ients wi th purified prote in derivative (PPD) or with 
dinitrochlorobenzene (DNCB). 
d Normal va lue of %E-RFC is 68% (±1O%). 
e N ot determined. 
estimating the cytotoxic index (CI) as 
% alive in C control - % alive in experiment 00 (" ) ------:-,..,.---,------~--- X 1 % 
% alive in C control 
Protein-A Rosette Assay 
Protein-A (Pharmacia Fine Chemicals, Uppsala, Sweden) was cou-
pled to rabbit red cells with chl'omic chloride according to Johnson's 
method [9]. T cells were purified from PBL of normal donors by E-
rosette depletion technique [10]. One hunw'ed ILl of T cell suspension 
(5 X lO';/ml) were mixed with equal volume of IgM rich fraction (20 
mg/ ml) separated from MF patients' sera by using ammonium sulfate 
precipitation and Bio-Gel Al.5m gel filtration and were incubated at 
4°C for 1 hr. After washing 3 times with PBS, the cells were suspended 
in 0.1 ml of RPMI-1640 and mixed with rabbit anti-human IgM anti-
serum. The cells were incubated at 4°C for 30 min, washed 3 times with 
PBS and suspended in 0.1 ml of RPMI-1640 medium. Equal volumes 
(0.1 ml) of the ce ll slIspension and 1% indicator red cells coated with 
protein-A were then admixed and spun at 200 g for 5 min. After 30 min 
at 4°C, the cells were gently suspended and the percentage of IgM-
binding cells which were rosetted with rabbit erythrocytes coated with 
protein-A was counted. 
RESULTS 
E-rosette Formation of PBL from MF Patients 
PBL were collected from 5 MF patients and thei.r ability to 
form E-rosettes was compared before and after culturing them 
for 20 hr in RPMI-1640 medium with 10% fetal calf serum 
(FCS) . As can be seen in Table II, depressed E-rosetting ability 
of MF patients' PBL, especially those from case 1 to 3, had 
recovered after the cultivation, showing almost normal levels of 
%E-RFC. 
Effect of Sera from MF Patients on E-rosette Formation of 
Normal PBL 
Since the data described above led us to consider a possible 
serum factor that can suppress E -rosette formation of human 
PBL, we tested the ability of MF patients' sera to interfere with 
E-rosette formation of PBL from allogeneic normal donors. 
Group A sera collected from MF patients (case 1-3) with low 
levels of %E -RFC showed E-rosette inhibition, whereas Group 
B sera obtained from MF patients (case 4 and 5) with almost 
normal levels of %E-RFC, as well as those from normal donors, 
had little effect on E-rosetting of normal PBL (Fig 1). 
E-rosetting ability of PBL and E-rosette inhibitory effect of 
MF sera were compared in a single patient (case 1) who was 
diagnosed as D'emblee type and had a fatal prognosis. Sera 
were collected sequentially from the patient and the %E-RFC 
of his PBL were counted simultaneously. As Fig 2 indicates, 
there was an inverse correlation between %E-RFC of the pa-
tient's PBL and the ability of the patient's serum to inhibit E-
rosette formation. 
TABLE II. E rosette formation of blood lymphocytes from MF 
patients before and after culturing those cells for 20 hr 
% E-rosette" 
Case no. 
PreclIltivation Postcultivation 
1 25 54 
2 11 48 
3 16 53 
4 70 72 
5 51 58 
" Percentage of E-rosetting lymphocytes in MF patients' blood was 
counted before and after cultming those cells in the presence of fetal 
calf serum. 
Partial Purification of E-rosette Inhibitory Factor from MF 
Serum 
Crude gamma-globulin fraction was prepared by 40% am-
monium sulfate precipitation from MF and control normal 
human sera and its inhibitory effect on E-rosette formation of 
normal PBL was tested by E-rosette inhibition assay. While 
crude gamma-globulin fraction from normal human serum 
showed little effect on E-rosetting, the same fraction obtained 
from MF serum showed E-rosette inhibitory activity. This 
activity was lost when the gammaglobulin fraction ofMF serum 
was treated with 2-ME (Table III). 
The crude gamma-globulin fraction prepru'ed from MF serum 
by ammonium sulfate precipitation was then separated by Bio-
Gel A1.5m column chromatography into 2 different fractions 
(Fig 3). As Table IV shows, E-rosette inhibitory activity was 
found in the fIrst fraction (F-1) but not in the second fraction 
ofMF serum samples, whereas those fractions of normal human 
serum had no inhibitory activities. When those 2 fractions of 
MF serum were incubated with rabbit anti-human IgM and 
IgG sera in double immunodiffusion plates, we found that th e 
fIrst fraction contained IgM but not IgG, whereas the second 
fraction had IgG but not IgM (data not shown) . 
In the next experiment, the fIrst fraction of Bio-Gel A1.5m 
effluent was further chromatographed by using Bio-Gel A5m 
column. As can be seen in Fig 4, the column effluent was 
separated into 4 different fractions, which were tested for E-
rosette inhibitory activity and IgM content. Among these frac-
tions, r elatively high E -rosette inhibition was observed with the 
second fraction (Table V), where IgM was also copmifIed (Fig 
5). 
Binding of IgM in MF Serum to T Cell Surfaces 
If the E-rosette inhibitory factor present in MF sera is an 
IgM antibody to human T cells, then one can expect that it 
migh t have cytotoxic effect on T cells. However, when we tested 
anti-T cell cytotoxic activity ofIgM rich fraction (F -1) separated 
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FIG 1. E-rosette inhibition induced by sera from MF patients and 
normal donors. MF sera were divided into 2 groups according to %E-
RFC of MF patients blood lymphocytes. Group A from case 1-3 
comprises sera obtained from MF patients with low level of %E-RFC, 
and group B from case 4 and 5 who had almost normal level of %E-
RFC. 
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FIG 2. Time sequence changes of rosette-forming cells and E-rosette 
inhibitory activity of sera from a single patient (case 1). E-RFC 
(e--e). EAC-RFC (A-A), EA(IgG)-RFC ( ___ ). Serum E-
rosette inhibi t ion (0--0). 
from MF serum by using 40% NH.SO. precipitation and Bio-
Gel Al.5m gel filtration, its cytotoxic activity was low, showing 
less than 20% CI against human T cells (Table VI). 
Because of the insensitivity of cytotoxic testing, we then 
employed more sensitive technique for detecting IgM binding 
to human T cell surfaces. For this purpose, we used indirect 
protein-A rosette assay and could fmd that more than 40% of 
human T cells could specifically adhere to IgM from the fraction 
(F-l) separated from MF serum by ammonium sulfate precipi-
tation and by Bio-Gel Al.5m filtration (Table VII). 
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TABLE III. E rosette inhibition induced by gamma-globulin 
prepared from MF serum by ammonium sulfate precipitation 
Sera used for E-rosette inhibition" 2-ME treatme nt 
Normal human serum 
Serum 
Gamma-globulin 
Gamma-globulin 
MF serum 
Serum 
Gamma-globulin 
Gamma-globulin 
+ 
+ 
% E-rosette inhibi-
tion 
4 
13 
10 
33 
40 
13 
"Human serum or its gamma-globulin fraction prepared by 40% 
ammonium sul fate saturation was incubated with normal human blood 
lymphocytes. The cells were then washed and tested fo r their abil ity to 
form E-rosettes. 
A280 
12 18 24 
Tube Number 
FIG 3. E lu tion proftle of crude gamma-globulin precipitated from 
MF serum by 40% ammonium sulfate saturation on Bio-Gel A1.5m 
ftItration. Two fractions (F-l , F-2) were collected and subjected to E-
rosette inhibition assay. 
TABLE IV. E-rosette inhibition induced by MF serum fractionated 
by using ammonium sulfate precipitation and Bio-Gel A l .Sm 
filtration 
Sera used for E-rosette %E-RFC % E-rosette inhibi-inhibitioncd, lion 
Normal human serum 
Fractlon-I (F -1) 62 5 
Fraction-2 (F-2) 66 0 
MF serum 
Fraction-I (F-I) 23 65 
Fraction-2 (F -2) 66 0 
No treatment 65 0 
"Crude gamma-globulin precipitated from human serum by 40% 
ammonium sulfate saturation was further separated into 2 fractions (F-
1, F-2) by Bio-Gel A1.5m column. 
"Normal human blood lymphocytes were incubated with each frac-
t ion, washed and tested for their ab ili ty to form E-rosettes. 
DISCUSSION 
The possibility that a certain serum factor might be respon-
sible for impaired E-rosette formation of T cells observed in 
MF patients [5] was suggested by the following observations; 
(1) depressed %E-RFC of MF patients' PBL could be normal-
ized by culturing them for 20 hI"; (2) sera collected from MF 
patients suppressed E-rosette formation of PBL from normal 
donors. Moreover, we have noticed in this preliminary experi-
May 1981 
ment that there exists a inverse correlation between %E-RFC 
of PBL from MF patients and the ability of their sera to inhibit 
E-rosette formation of normal T cells . Thus, the sera from 
patients with low levels of %E-RFC showed greater E -rosette 
inhibitory activity than those sera collected from MF patients 
with almost normal levels of %E-RFC. This is also the case in 
a single MF patient, whose sera were sequentially collected and 
E-rosette inhibitory activities were compared to %E-RFC of 
this patient's PBL at each time when the serum samples were 
collected. 
A280 
0.5 
A B C D 
10 16 22 
Tube Number 
FIG 4. Elution proftle orBio-Gel A1.5m F-1 fractio n on Bio-Gel A5m 
gel filtration. Four different fractions (A, B, C, D) were collected and 
subjected to E-rosette inhibition assay. 
TABLE V. Further purification of E·rosette inhibitory factor by 
using Bio-Gel A5m Gel filtration 
Fractions used for E-ro-
sette inhibition,,·b 
MF serum 
Fraction A 
Fraction B 
Fraction C 
Fraction D 
No treatment 
%E-RFC 
67 
48 
59 
63 
73 
% E-rosette Inhibition 
12 
34 
19 
13 
o 
"The fiest fraction (F-1) obtained from MF serum by Bio-Gel A1.5m 
ftltration was further separated into four different fractions by using 
Bio-Gel A5m column. 
I, Normal blood T lymphocytes were incubated with each fraction, 
washed and tested for their ability to form E-rosettes. 
FIG 5. Double immunodiffusion us ing anti-human IgM in the center 
well and Bio-Gel A5m fractions (A, B, C, D) in the peripheral wells. 
Well E and F contain purified human IgM from macroglobulinemia 
patient and PBS, respectively. 
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TABLE VI. Cytotoxic activity of MF serum. against T cells 
Donor-I" Donor-2" 
Sera 
%CI %EI %CI %EI 
ATS" 98 100 89 100 
MFS c 14 31 18 40 
NHS" 4 4 6 8 
n T cells were separated by E-rosette depletion technique from PBL 
obtained from 2 normal donors. 
/, Rabbit anti-human thymocyte serum was prepared by the method 
previously described (see ref. 6 and 8). 
,. Serum obtained from a MF patient. 
d Normal human serum. 
TABLE VII. Binding of IgM from MF serum to T cell surfaces as 
defined by indirect protein A rosette assay 
1st reagent (F-1 frac- 2nd reagent % Protein A ro- % Specific Pro-(anti-human tion)" IgM) sette tein A RFC" 
MF Patient 
Case-l + 67 41 
Case-2 + 69 43 
Healthy donor + 27 1 
None + 26 0 
None 14 - 12 
" F-1 fraction was obtained from MF or normal serum by using 40% 
ammonium sulfate saturation and Bio-Gel A1.5m gel fil trat ion. 
"Percentage of Protein A rosette form ing cells (RFC) was subtracted 
by that of RFC treated with the second reagent (anti-IgM) a lone. 
Defective E-rosette formation of T lymphocytes has been 
observed in association with a variety of diseases including 
cancer [11], autoimmune disease [12], viral infection [13], sar-
coidosis [14] and Hodgkin's disease [15]. In some of these cases, 
certain serum factors responsible for impaired E-rosette for-
mation have been reported [13-15]. Thus, Chisari and Edging-
ton [13] have reported that beta-lipoprotein of the low-density 
lipoproteins from sera of patients with hepatitis B has E-rosette 
inhibitory activity. Menzoian et aI [16], on the other hand, have 
shown that immunoregulatory alpha-globulin can inhibit E-
rosetting by T cells. In contrast to these studies, it has also been 
reported that E-rosette inhibitory serum factors are present in 
the gamma-globulin fraction in cases of Hodgkin's disease [15] 
and sarcoidosis [14]. The latter observation seems to be similar 
to our data indicating that the E-rosette inhibitory factor found 
in MF patients' sera was 2-ME-sensitive and could be copurified 
with serum IgM by using ammonium sulfate precipitation and 
gel filtrations. This factor might be an IgM antibody to T cells 
occuring naturally during the disease process but it has low 
complement-dependent cytotoxicity unlike natural antithymo-
cytotoxic antibody in SLE patients [12] or anti-T cell antibody 
found in sarcoidosis patients [14]. It is likely that E-rosette 
inhibitory factors detected in different diseases are heteroge-
neous and participate in immune disfunction observed in such 
diseases. 
The fact. that MF patients who had low %E-RFC and high E-
rosette inhibitory serum activity had poor prognosis, whereas 
those patients with normal levels of %E-RFC and little E-
rosette inhibitory serum activity had better clinical courses 
suggests that measuring the serum inhibitory factor in MF 
patients may provide a valuable tool for the confirmation of 
disease activity and prognosis in those patients. To confi.rm this 
possibility, further clinical study with a large number of MF 
patients is clearly required and the study is now being under-
taken. 
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